🔗 Share this article

As the United States proceeds with sweeping adjustments to its vaccine guidelines, one figure has emerged unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on COVID-19 shots throughout the global health crisis and has zeroed in on potential deaths following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Health officials had intended to announce sweeping changes to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with many the international standard with no evidence for benefit. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood vaccine recommendations in the US to become more in line with Denmark, a society with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Questions Over Qualifications

The appointee has no apparent experience in medication creation, approval processes or administrative roles, which has been standard for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of medication creation”, noted Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

This division has an immense range of responsibilities at the agency, she emphasized.

“The public just pays attention on the innovative therapies, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and each of these need to be looked after,” Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major administrative aspect to the job, which manages in excess of 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Controversial Policies

When asked about questions about Høeg’s fitness for the role and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries are based on inaccurate premises”.

“This background matches the functions of her position,” the spokesperson explained, pointing to the period Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's controversial priority voucher program, a disputed one-day therapy clearance system that allegedly concerned her predecessors. “How are these therapies being picked for this voucher program? Who is making the choices?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards more relaxed oversight of all drugs, with the exception of shots.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, history, critics said. She published a analysis using non-validated volunteer-provided data to estimate the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership featured changing rules for recently developed shots and ending “optional” immunizations, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has according to sources suggested excluding adolescent males from getting COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to accommodate the science in a very disingenuous, untruthful fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|